TSX closed
Loading markets…

Advertisement

PARTNER SPOTLIGHT

CIBC Investor's Edge

Invest your way with confidence.

  • ✓Powerful tools & research — at no extra cost
  • ✓Stocks, ETFs, options & more
  • ✓Competitive fees + USD accounts
Stocks/TSX/MDP

Medexus Pharmaceuticals Inc (MDP : TSX)

Common Stock

$4.99

CAD

+0.12 (2.46%)

Last updated: 2026-10-08

Follow MDP

MDP

Medexus Pharmaceuticals Inc

Source:WealthAwesomeWealthAwesome
↓ $0.14 (-2.73%)
30 day period
$4.72$4.98$5.24Aug 27Sep 18Oct 8

Performance

1 Day

+2.46%

1 Week

+1.42%

1 Month

-1.77%

YTD

+61.49%

Key Statistics

Market Cap

$153.04M

52W High

$5.50

52W Low

$2.51

P/E Ratio

-

50 Day MA

$5.07

200 Day MA

$3.98

Beta

1.73

Dividend Yield

-

Advertisement

Technical Indicators

Price vs 50-Day SMA

↓Below 50 SMA

Price vs 200-Day SMA

↑Above 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
10/8/2026$4.89$4.99$4.76$4.99$4.9963,905
10/7/2026$4.79$4.95$4.79$4.87$4.8739,645
10/6/2026$4.90$4.91$4.76$4.83$4.8330,245
10/5/2026$4.61$4.95$4.61$4.90$4.9043,798
10/2/2026$4.89$4.93$4.57$4.72$4.72106,433
10/1/2026$4.99$4.99$4.86$4.92$4.9224,832
9/30/2026$5.00$5.01$4.87$5.00$5.0056,784
9/29/2026$5.10$5.10$4.93$5.00$5.0038,303
9/28/2026$5.13$5.13$5.07$5.12$5.1215,975
9/25/2026$5.12$5.14$4.96$5.12$5.1222,901

Analyst Price Targets

Based on analyst covering MDP · as of Sep 17, 2026

📈

Wall Street analysts forecast MDP stock price to rise 45.3% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$7.25

+45.3% Upside

Current Price

C$4.99

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on MDP's historical volatility

HistoricalForecast68%95%
C$3.30C$4.03C$4.75C$5.48C$6.21C$6.93TodayJun 2Aug 6Oct 8Nov 20Jan 3Feb 15

30-Day Vol

28.5%

Annualized

90-Day Vol

39.1%

Annualized

Trend (90d)

-11.6%

Annualized drift

90d Mean

C$4.79

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$4.92C$4.46 – C$5.43
60 trading daysC$4.85C$4.22 – C$5.58
90 trading daysC$4.79C$4.04 – C$5.68

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis; Rupall, a prescription allergy medication; and GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; and intraarticular, a triamcinolone hexacetonide injectable suspension. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.

Financials

Revenue (TTM)
$103.30M
EBITDA
$16.64M
Profit Margin
-2.29%
ROE (TTM)
-4.68%
EPS (Diluted)
-0.10
Book Value
2.13

Classification

Sector
Health Care
Industry
Pharmaceuticals
Group
Pharmaceuticals, Biotechnology & Life Sciences

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report

Advertisement

Common Questions About MDP

Market movers

Recent TSX movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
FTGFiran Technology Group Corporation$32.00+25.93%
BNGBengal Energy Ltd$0.03+25.00%
PRNProfound Medical Corp$9.84+20.59%
RCHRichelieu Hardware Ltd.$38.63+11.39%
LUCLucara Diamond Corp$0.15+11.11%
TVA-BTVA Group Inc$2.49+10.67%
THNCThinkific Labs Inc$2.05+10.22%
MCBMccoy Global Inc$2.65+9.50%

MDP.TO news timeline

15 articles covering MDP.TO, most recent first

Latest

Why Medexus Pharmaceuticals Inc stock is rising today

•Stocks

Advertisement